The FDA’s decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment from Alzheimer’s.
More Stories
Metaplex unveils indexing and data availability network for Solana
Metaplex Foundation announced the Metaplex Aura Network on September 23, 2024. Aura is a decentralised indexing and data availability platform...
Levi’s teases Beyoncé collaboration as denim trend takes hold
Levi Strauss created fan buzz on Monday after teasing a future collaboration with Beyoncé through a post on Instagram.
Boeing sweetens labor proposal in ‘best and final’ offer as strike enters second week
The new offer includes higher pay raises, reinstated annual bonuses and an increased ratification bonus, among other changes, Boeing said...
ARKM up 27% as AI tokens surge
Arkham is among the top trending artificial intelligence-related token as the price of its native token ARKM surges more than...
Southwest Airlines tells staff ‘difficult decisions’ ahead in push to boost profits
Southwest will provide more detail about its plans to raise profits at an investor day on Sept. 26.
AAVE price surges to 2-year high
AAVE price reached highs of $173 on Monday, its highest level since April 2022. TVL has also recovered as the...